US EQUITIES CLOSED CRYPTO 24/7
HALAL TRADING ROOM Sharia-screened signals
TERMINAL
05

0512.HK

Stock Grand Pharmaceutical Group Limited
$4.74

Hong Kong Stock Exchange · Healthcare · HK

Sharia status
COMPLIANT
Per In-house ratio engine · assessed 2026-08-27
HTR non-permissible income 0.06%
🕌Open research, not a fatwa — verify with your own scholar.
Trade setup SEPARATE FROM SHARIAH
No active setup right now. The technical picture doesn't show a clear edge — check back when the trend or momentum shifts.

Grand Pharmaceutical Group Limited (0512.HK) is currently considered halal (Sharia-compliant), per In-house ratio engine (last assessed 2026-08-27). See the full ratio breakdown and business-activity screen below for the reasoning.

Market & analysts
Price target
$9.53
+101.2% · 3 analysts
Institutional own.
16.9%
of shares
COMPLIANT
Sharia compliance
0.06%
Non-permissible income — HTR, from filings (2025-12-31)
$9.53
Price target (+101.2%) · 3 analysts
16.9%
Institutional ownership

🕌 In-house Compliance Research

Computed from Yahoo Finance fundamentals (Tier-4 provider, no filing available), balance sheet as of 2025-12-31. 0512.HK files no SEC reports, so these ratios come from the issuer's own published statements rather than XBRL.

Business activity: cleared (no excluded categories detected)

AAOIFI Pass

RatioValueThresholdResult
Interest-bearing debt 26.11% 30.00% Pass
Interest-bearing investments 11.30% 30.00% Pass
Non-permissible income 0.06% 5.00% Pass

Usmani Pass

RatioValueThresholdResult
Interest-bearing debt 17.58% 33.00% Pass
Interest-bearing investments 7.61% 33.00% Pass
Non-liquid assets 85.77% at least 20.00% Pass
Non-permissible income 0.06% 5.00% Pass

MSCI Pass

RatioValueThresholdResult
Interest-bearing debt 17.58% 33.33% Pass
Cash + interest-bearing securities 7.61% 33.33% Pass
Accounts receivable 14.23% 33.33% Pass
Non-permissible income 0.06% 5.00% Pass

FTSE Pass

RatioValueThresholdResult
Interest-bearing debt 17.58% 33.33% Pass
Cash + interest-bearing securities 7.61% 33.33% Pass
Accounts receivable 14.23% 50.00% Pass
Non-permissible income 0.06% 5.00% Pass

Dow Jones Islamic Market Pass

Scored against a trailing-average market cap (24-month), share-weighted by the issuer's own reported share counts — not today's market cap.

RatioValueThresholdResult
Interest-bearing debt 19.58% 33.00% Pass
Cash + interest-bearing securities 8.48% 33.00% Pass
Accounts receivable 7.38% 33.00% Pass
Non-permissible income 0.06% 5.00% Pass

S&P Shariah Pass

Scored against a trailing-average market cap (36-month), share-weighted by the issuer's own reported share counts — not today's market cap.

RatioValueThresholdResult
Interest-bearing debt 22.67% 33.00% Pass
Cash + interest-bearing securities 9.81% 49.00% Pass
Accounts receivable 8.55% 49.00% Pass
Non-permissible income 0.06% 5.00% Pass

MSCI M-Series Pass

Scored against a trailing-average market cap (36-month), share-weighted by the issuer's own reported share counts — not today's market cap.

RatioValueThresholdResult
Interest-bearing debt 22.67% 33.33% Pass
Cash + interest-bearing securities 9.81% 33.33% Pass
Accounts receivable 18.36% 49.00% Pass
Non-permissible income 0.06% 5.00% Pass

Research only, not investment advice. Thresholds are each standard-setter's published limits; a ratio marked “at least” is a floor, not a ceiling.

8.647.626.615.594.572025-09-122026-03-162026-09-11

Pinch or scroll to zoom · drag to pan — both axes move · double-click to reset

Support & Resistance
S3
4.58
S2
4.70
S1
4.77
PIVOT
4.88
R1
4.95
R2
5.06
R3
5.13

Classic floor-trader pivots from the last completed daily bar. Highlighted pills are the levels bracketing the current price.

Price Forecast

7-day expected range
4.34 5.41
±10.89% from 4.88, made 2026-09-03 · resolves 2026-09-10
STRONG SELL
from 19 indicators
Not enough resolved predictions yet — 0 of 10 needed before we publish an accuracy figure. 22382 forecast(s) are currently open and will be scored automatically when their horizon expires.

The range is measured volatility (ATR over the horizon), not a target — a wider band means a more volatile asset, not a stronger view. The direction is the indicator tally above. Every forecast is recorded when made and scored against the real price when it comes due, including the wrong ones. Not a recommendation, and not a fatwa.

Technical Summary

STRONG SELL
19 indicators
OscillatorsNEUTRAL
3 buy · 1 neutral · 3 sell
Moving averagesSTRONG SELL
0 buy · 0 neutral · 12 sell
Every indicator, and what it reads
IndicatorValueSignal
RSI (14)34.00NEUTRAL
Stochastic %K (14)3.65BUY
CCI (20)-124.00BUY
Williams %R (14)-96.35BUY
MACD (12,26,9)-0.04SELL
ROC (10)-9.64SELL
Momentum (10)-0.50SELL
EMA (10)4.93SELL
SMA (10)4.91SELL
EMA (20)5.03SELL
SMA (20)5.11SELL
EMA (30)5.08SELL
SMA (30)5.15SELL
EMA (50)5.15SELL
SMA (50)5.17SELL
EMA (100)5.46SELL
SMA (100)5.27SELL
EMA (200)6.34SELL
SMA (200)6.33SELL

Standard indicator thresholds (RSI 30/70, Stochastic 20/80, CCI ±100, Williams %R −80/−20, MACD histogram sign, price vs. average) computed on daily bars. A summary of what common indicators say — not a recommendation, and not this site's own trading verdict.

About Grand Pharmaceutical Group Limited

Healthcare · Drug Manufacturers - Specialty & Generic

Grand Pharmaceutical Group Limited, an investment holding company, engages in the research and development, manufacture, and sale of pharmaceutical preparations and medical devices, biotechnology and healthcare products, and pharmaceutical raw materials. The company offers respiratory, ophthalmology, cerebro-cardiovascular emergency, and biotechnology related products. It manufactures and sells pharmaceutical, taurine, agrochemicals, chemical medicine, and amino acid series products. In addition, the company provides bio-pesticides and additives; disposal surgical products; and Chinese medicine, and health food products. The company has a strategic cooperation agreement with the Eye Hospital of Wenzhou Medical University in the field of ophthalmic drug research and development. It operates in the People's Republic of China, the rest of Asia, the United States, Europe, and internationally. The company has a strategic partnership with the University of Hong Kong for the research and development of drugs in the field of anti-infection and the industrialization of the research results. The company was formerly known as China Grand Pharmaceutical and Healthcare Holdings Limited. The company was incorporated in 1995 and is based in Central, Hong Kong.

grandpharm.com ↗

Background via Yahoo Finance — informational, not part of the verdict.

SMC — Top Down

Not enough price history yet for a smart-money structure read on any timeframe.

Momentum & Volume

Peer Movement

Peer movement computing — it will appear here on its own.

Insider Activity (90d)

NO DATA   0 buys · 0 sells

COT Positioning — E-MINI S&P 500 - CHICAGO MERCANTILE EXCHANGE

NEUTRAL   report date 2026-09-08 · Asset managers net 912361 (-21819)

AI Summary

Plain-language summary of the evidence already on this page — the Sharia screen, structure, momentum, and order flow above. It explains the read; it doesn't make the call. Generated on demand (a live AI call), never run automatically.

Tell us what's working, what's confusing, or what you want to see next — read by a real person, not a form that goes nowhere.